VANCOUVER, July 9, 2012 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex")
(OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the
company's lead compound for Alzheimer's disease currently in human
clinical trials, will be presented in a poster session at the 2012
Alzheimer's Association International Conference (AAIC) in Vancouver,
The ANAVEX 2-73 poster will be presented by Tangui Maurice, PhD, CNRS
Research Director, Team II Endogenous Neuroprotection in
Neurodegenerative Diseases INSERM, University of Montpellier.
Presentation details are as follows:
Monday, July 16, 2012
1 p.m. to 3:30 p.m.
Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran
derivative targeting the sigma-1 chaperone protein, in a mouse model of
Alzheimer's disease: Analyses of administration schedules and
combination studies with donepezil and memantine
Note to editors: Pursuant to AAIC policy, the abstract for this poster
presentation cannot be disclosed until the formal presentation has been
Any parties interested in meeting with the Anavex team at AAIC may
contact the company's communications team at +1 (416) 489-0092 or email@example.com.
AAIC 2012 takes place Saturday, July 14 to Thursday, July 19, 2012 in
Vancouver. It is the world's premiere forum for reporting and
discussion of groundbreaking research and information on the cause,
diagnosis, treatment and prevention of Alzheimer's disease and related
disorders. Additional information about the conference is available at
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug
candidates. Anavex utilizes its proprietary SIGMACEPTOR Platform to
develop drug candidates targeting specific clinical indications. Lead
compound ANAVEX 2-73, developed to treat Alzheimer's through disease
modification, is in human clinical trials. A Phase 1 single ascending
dose study of ANAVEX 2-73 was successfully completed in Germany in
2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and
neuroprotective properties, and that it is well tolerated in doses up
to 55mg. The company is preparing to embark on a multiple ascending
dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded
corporation quoted as AVXL.
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements are only
predictions based on current information and expectations and involve a
number of risks and uncertainties. Forward-looking statements in this
press release include that Dr. Maurice will make a presentation at AAIC
in Vancouver; that the presentation will pertain to Anavex and ANAVEX
2-73, its lead drug candidate for Alzheimer's disease; that we are
moving forward with clinical trials; and that data from a prior trial
indicates that the compound is well tolerated. Actual events or
results may differ materially from those projected in any of such
statements due to various factors, including the risks and
uncertainties inherent in drug discovery and development, which
include, without limitation, the potential failure of development
candidates to advance through preclinical studies or demonstrate safety
and efficacy in clinical testing and the ability to pass clinical
trials so as to move on to the next phase, our ability to finance
development or satisfy the rigorous regulatory requirements for new
drugs, our ability to attract and retain quality personnel, and that
despite positive results, our competitors may offer better or cheaper
alternatives. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof. All forward-looking statements are qualified in their entirety
by this cautionary statement and Anavex Life Sciences Corp. undertakes
no obligation to revise or update this press release to reflect events
or circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
Shareholder & Media Relations
Outside North America: +1 (416) 489-0092
SOURCE Anavex Life Sciences Corp.